Navigation Links
Shire Celebrates World Rare Disease Day on February 28
Date:2/26/2009

HGT business unit joins the global rare disease community to raise awareness for underserved populations; launches online resource to unite patient community

CAMBRIDGE, Mass., Feb. 26 /PRNewswire/ -- Shire Human Genetic Therapies (HGT), a business unit of Shire plc, the global specialty biopharmaceutical company, today announced it will join together with the National Organization of Rare Diseases (NORD) to celebrate World Rare Disease Day on February 28, 2009. The purpose of this day is to call attention to the public health issues associated with rare diseases, which affect nearly 30 million Americans and countless others around the world.

In addition to supporting advocacy-driven partnership activities, which include a grassroots video campaign and outreach to policy makers to encourage better access to treatment and increased reimbursement for orphan drugs, Shire HGT is developing a new, comprehensive online resource center, set to launch in early 2009. This new online resource--called the BRAVE Community--is designed to help patients find important medical information and connect with one another. Shire HGT is inviting the rare disease community to visit http://www.BRAVECommunity.com to sign up to request information about specific rare genetic diseases and to be notified by email when the website officially launches.

"The rare disease community is often overlooked by others in the industry, which is why it gives us great pleasure to celebrate World Rare Disease Day," said Sylvie Gregoire, President of Shire HGT. "Our organization is committed to enabling people with life-altering conditions to lead better lives--and for Shire, this includes improving access to information as well as providing therapies for these diseases."

A rare disease is one that affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. While rare individually, NORD estimates that collectively, rare diseases affect nearly 1 in 10 Americans.

"People with rare diseases remain a medically underserved population in every country," said Peter Saltonstall, president of NORD, which is sponsoring Rare Disease Day in the U.S. "This day is intended to bring together the patients and families with rare disease to discuss the need for greater awareness, more research, and better access to treatment."

About Rare Disease Day

Rare Disease Day began in 2008 in Europe. In 2009, Rare Disease Day will be observed on a global basis with participation from the United States, Canada, Australia and China, among others. For more information on Rare Disease Day visit the Rare Disease Day website at http://www.rarediseaseday.org.

About NORD

NORD, a federation of individuals and patient organizations, was established in 1983 by the patient leaders who worked to get the Orphan Drug Act passed. It provides advocacy in Washington, DC, on behalf of the rare disease community; research grants and fellowships; educational services for patients, the public, and medical professionals; and patient assistance programs. You may support NORD's initiatives by spreading the word and sharing your story at http://www.rarediseaseday.org/yourstory.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire Human Genetic Therapies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions
2. Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions
3. Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List
4. Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations
5. New Hampshire Seniors Speak Out Against Medicare Advantage Cuts
6. Proposed Congressional Legislation Would Cut $6.6 Million from the Medicare Advantage Program in New Hampshire
7. State, National Long Term Care Community Applauds New Hampshire Leader in U.S. Senate for Helping Lead Effort to Block $770 Million Bush Medicare Cuts
8. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
9. Anthem Blue Cross and Blue Shield in New Hampshire Announces Unique Enhancement to its ePrescribing Program
10. Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
11. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: